Clinical Trials to Compare the Effects of Pioglitazone and Evogliptin on Hepatic Fibrosis in Patients With Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes

  • STATUS
    Recruiting
  • End date
    May 25, 2022
  • participants needed
    40
  • sponsor
    Yonsei University
Updated on 25 January 2021

Summary

The clinical study determines the effect of Evogliptin in patients with type 2 diabetes mellitus and chronic hepatitis B to confirm the improvement of hepatic fibrosis.

Details
Condition Chronic Hepatitis B With Significant Hepatic Fibrosis With Type 2 Diabetes
Treatment gluconon tab 15mg, suganon tab 5mg
Clinical Study IdentifierNCT04584242
SponsorYonsei University
Last Modified on25 January 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Adultes between 20 and 80 years of age
Patients who satisfy the following conditions among chronic hepatitis B patients diagnosed with type 2 diabetes
Patients who are newly diagnosed as type 2 diabetes : 6.5% HbA1c < 10.0%
Patients who are already diagnosed as type 2 diabetes: HbA1c < 10.0%
Patients who have significant liver fibrosis of at least 7 kPa in a hepaticity test using fibroscan
Patients who voluntarily signed the consent form after informed on the object, method, benefits and risks of the clinical study

Exclusion Criteria

Patients who were taking Pioglitazone or Evoglipitin medication or who took diabetes medication within 4 weeks at the time
Patients who meet the standard of alcoholic fatty liver (in excess of 210g per week for men and 140g per week for women over the last two years)
Liver cirrhosis patients with impaired liver function (CTP class B and C)
Patients who took drugs that can cause fatty liver (amiodarone, methotrexate, tamoxifen, valproate, corticosteroids, etc.)
Patients with acute or chronic metabolic acidosis with or without coma and history of ketonic acid (within 24 weeks)
Allergic or hypersensitive to the target drug or its composition
Patients treated with oral or non - oral corticosteroid treatment for chronic (more than 14 consecutive days) within 8 weeks prior to screening
Poor nutrition, starvation, and debilitating conditions (including severe infections and severe injury patients before and after surgery)
Patients who are receiving radiation and chemotherapy for malignant tumors or patients who have been on chemotherapy or radiation treatment for less than two years
Patients with heart failure in 24 weeks (class III to IV in NYHA classification) or unregulated arrhythmia
Patients with acute cardiovascular disease in 12 weeks or less (e.g. unstable angina, myocardial infarction, routine ischemic seizures, cerebrovascular disease, coronary bypass surgery, or coronary artery interventions)
Patients with renal failure, chronic neuropathy (estimated glomerular filtration rate <60 mL/min/1.73 m2) or dialysis
Anemia patients whose Hb levels are less than 10.5g/dl
Women who are pregnant or breastfeeding
Patients who do not agree to use proper contraception during clinical trials only for women or men
Patients who took medicines for clinical trials in other clinical trials within four weeks of document consent
Patients who are unable to participate in clinical trials on the judgment of other researchers
Patients who cannot read the consent form (e.g. illiteracy, foreigners, etc.)
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

Phone Email

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note